July 23, 2014 10:07 PM ET

Biotechnology

Company Overview of Genelux Corporation

Company Overview

Genelux Corporation, a biomedical company, develops diagnostic and therapeutic solutions for cancer and inflammatory diseases. Its product GL-ONC1 is a genetically stable oncolytic virus strain to locate, enter, colonize, and destroy cancer cells without harming healthy tissues or organs. Genelux Corporation was founded in 2001 and is headquartered in San Diego, California. The company has locations in Redlands, California; and Bernried, Germany.

3030 Bunker Hill Street

Suite 300

San Diego, CA 92109 5754

United States

Founded in 2001

Phone:

858-483-0024

Fax:

858-483-0026

Key Executives for Genelux Corporation

Chief Executive Officer
Chief Financial Officer
Age: 52
Chief Operating Officer
Chief Executive Officer of Genelux Europe and President of Genelux Europe
Compensation as of Fiscal Year 2014.

Genelux Corporation Key Developments

Genelux Announces Board Appointments

Genelux has appointed George Vandeman, long-time Amgen executive, and Thomas Zindrick, newly appointed Genelux President and CEO of Genelux, to the company's Board of Directors. Vandeman has also been named Vice Chairman and is the Board's fifth independent Director. Together, the appointments expand the Genelux Corp. Board to nine members.

Genelux Corporation Announces Board Changes

Genelux Corporation announced the appointment of Mr. George Vandeman, long-time Amgen executive, and Thomas Zindrick, newly appointed Genelux President and CEO of Genelux Corporation, to the company's Board of Directors. Mr. Vandeman has also been named Vice Chairman and is the Board's fifth independent Director. Together, the appointments expand the Genelux Corporation Board to nine members. Vandeman retired in 2000 after five years at Amgen as Senior Vice President, General Counsel and Chairman of the company's Operating Committee. Thomas Zindrick, also named to the Board of Directors, was recently appointed CEO and president of Genelux Corporation, succeeding founder and former CEO and President, Aladar A. Szalay, Ph.D. Prior to Genelux, Mr. Zindrick was CEO of Amitech Therapeutic Solutions Inc.

Genelux Corporation Announces Management Changes

Genelux Corporation announced that Aladar Szalay, PhD has chosen to retire from the positions of Chairman, President and CEO of Genelux for personal reasons. Dr. Szalay will continue to serve as chief scientific advisor to the CEO and remain on the company's board of directors as chairman emeritus. Effective May 2, 2014, Mr. Thomas Zindrick will serve as president and CEO. Mr. James L. Tyree, formerly of Abbott will serve as chairman of the board. Prior to Genelux, Zindrick was CEO of Amitech Therapeutic Solutions Inc.

Similar Private Companies By Industry

Company Name Region
Biohelix Corporation United States
Lazarus Therapeutics LLC United States
KinDex Pharmaceuticals, Inc. United States
CP Meilland, LLC United States
Diomics Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genelux Corporation, please visit www.genelux.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.